Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

被引：0
|
作者：
机构：
[1] Lancet Oncol, 125 London Wall, London EC2Y 5AS, England
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 04期
关键词：
D O I：
10.1016/S1470-2045(23)00111-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E145 / E145
页数：1
相关论文
共 50 条
  • [31] Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    Makker, Vicky
    Rasco, Drew
    Vogelzang, Nicholas J.
    Brose, Marcia S.
    Cohn, Allen L.
    Mier, James
    Di Simone, Christopher
    Hyman, David M.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Schmidt, Emmett V.
    Guo, Matthew
    Sachdev, Pallavi
    Shumaker, Robert
    Aghajanian, Carol
    Taylor, Matthew
    LANCET ONCOLOGY, 2019, 20 (05): : 711 - 718
  • [32] An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
    Dummer, R.
    Rinderknecht, J.
    Goldinger, S. M.
    Wagner, I.
    Mitchell, L.
    Veronese, M. L.
    Nick, S.
    Hilfiker, P.
    Gobbi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Effects of resveratrol on aortic growth in patients with Marfan syndrome: a single-arm open-label multicentre trial
    van Andel, Mitzi Marlotte
    Bosshardt, Daan
    Schrauben, Eric M.
    Merton, Renske
    van Kimmenade, Roland R. L.
    Scholte, Arthur
    Dickinson, Michael G.
    Robbers-Visser, Danielle
    Zwinderman, Aeilko H.
    Mulder, Barbara
    Nederveen, Aart J.
    van Ooij, Pim
    Groenink, Maarten
    de Waard, Vivian
    HEART, 2025, 111 (01) : 11 - 17
  • [34] Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
    Priscilla K. Brastianos
    Eudocia Quant Lee
    Justine V. Cohen
    Sara M. Tolaney
    Nancy U. Lin
    Nancy Wang
    Ugonma Chukwueke
    Michael D. White
    Naema Nayyar
    Albert Kim
    Christopher Alvarez-Breckenridge
    Ian Krop
    Maura Keeley Mahar
    Mia S. Bertalan
    Brian Shaw
    Joana L. Mora
    Nathaniel Goss
    Megha Subramanian
    Lakshmi Nayak
    Jorg Dietrich
    Deborah A. Forst
    Brian V. Nahed
    Tracy T. Batchelor
    Helen A. Shih
    Elizabeth R. Gerstner
    Beverly Moy
    Donald Lawrence
    Anita Giobbie-Hurder
    Scott L. Carter
    Kevin Oh
    Daniel P. Cahill
    Ryan J. Sullivan
    Nature Medicine, 2020, 26 : 1309 - 1309
  • [35] CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
    Hodi, F. Stephen
    Amen, Asim
    Saenger, Yvonne M.
    Pennock, Gregory K.
    Guthrie, Troy H.
    Salama, April K.
    Flaherty, Lawrence E.
    Koon, Henry B.
    Lawson, David H.
    Shaheen, Montaser F.
    Balogh, Agnes
    Konto, Cyril
    O'Day, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Zimmer, Lisa
    Eigentler, Thomas K.
    Kiecker, Felix
    Simon, Jan
    Utikal, Jochen
    Mohr, Peter
    Berking, Carola
    Kaempgen, Eckhart
    Dippel, Edgar
    Stadler, Rudolf
    Hauschild, Axel
    Fluck, Michael
    Terheyden, Patrick
    Rompel, Rainer
    Loquai, Carmen
    Assi, Zeinab
    Garbe, Claus
    Schadendorf, Dirk
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [37] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Andrea Necchi
    Salvatore Lo Vullo
    Luigi Mariani
    Daniele Raggi
    Patrizia Giannatempo
    Giuseppina Calareso
    Elena Togliardi
    Flavio Crippa
    Nicola Di Genova
    Federica Perrone
    Maurizio Colecchia
    Biagio Paolini
    Giuseppe Pelosi
    Nicola Nicolai
    Giuseppe Procopio
    Roberto Salvioni
    Filippo G. De Braud
    Investigational New Drugs, 2016, 34 : 236 - 242
  • [38] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Thomas K. Eigentler
    Felix Kiecker
    Jan Simon
    Jochen Utikal
    Peter Mohr
    Carola Berking
    Eckhart Kämpgen
    Edgar Dippel
    Rudolf Stadler
    Axel Hauschild
    Michael Fluck
    Patrick Terheyden
    Rainer Rompel
    Carmen Loquai
    Zeinab Assi
    Claus Garbe
    Dirk Schadendorf
    Journal of Translational Medicine, 13
  • [39] Intraoperative radiotherapy for brain metastases: first-stage results of a single-arm, open-label, phase 2 trial
    de Castro, Douglas Guedes
    Sanematsu Junior, Paulo Issamu
    Assis Pellizzon, Antonio Cassio
    Suzuki, Sergio Hideki
    Fogaroli, Ricardo Cesar
    Souza Dias Junior, Jose Eduardo
    Melo Gondim, Guilherme Rocha
    Estrada, Daniel Alvarez
    Gobo Silva, Maria Leticia
    Rassi, Marcio Saquy
    Chen, Michael Jenwei
    Giacomelli, Richard
    Ramos, Henderson
    Neto, Elson Santos
    Abrahao, Carolina Humeres
    Coelho, Tharcisio Machado
    Yu, Liao Shin
    de Queiroz Tannous, Cassio
    Calsavara, Vinicius Fernando
    Giordano, Frank Anton
    de Oliveira, Jean Goncalves
    JOURNAL OF NEURO-ONCOLOGY, 2023, 162 (01) : 211 - 215
  • [40] An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
    Necchi, Andrea
    Lo Vullo, Salvatore
    Mariani, Luigi
    Raggi, Daniele
    Giannatempo, Patrizia
    Calareso, Giuseppina
    Togliardi, Elena
    Crippa, Flavio
    Di Genova, Nicola
    Perrone, Federica
    Colecchia, Maurizio
    Paolini, Biagio
    Pelosi, Giuseppe
    Nicolai, Nicola
    Procopio, Giuseppe
    Salvioni, Roberto
    De Braud, Filippo G.
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (02) : 236 - 242
12345